Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

$3.73

+0.41 (+12.35%)

(As of 11/4/2024 ET)

Zentalis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 10 Analyst Ratings

Sell
0

Hold
7

Buy
3

Based on 10 Wall Street analysts who have issued ratings for Zentalis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a buy rating for ZNTL.

Consensus Price Target

$10.78
188.95% Upside

According to the 10 analysts' twelve-month price targets for Zentalis Pharmaceuticals, the average price target is $10.78. The highest price target for ZNTL is $20.00, while the lowest price target for ZNTL is $4.00. The average price target represents a forecasted upside of 188.95% from the current price of $3.73.

Get the Latest News and Ratings for ZNTL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors.

ZNTL Analyst Ratings Over Time

Type	Current Forecast 11/6/23 to 11/5/24	1 Month Ago 10/7/23 to 10/6/24	3 Months Ago 8/8/23 to 8/7/24	1 Year Ago 11/6/22 to 11/6/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	7 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.78	$10.78	$11.33	$47.50
Forecasted Upside	188.95% Upside	219.82% Upside	245.53% Upside	280.61% Upside
Consensus Rating	Hold	Hold	Hold	Buy

10 EV Stocks to Buy Right Now (Ad)

EV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.

Click here to view all 10 stocks right away.

ZNTL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZNTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zentalis Pharmaceuticals Stock vs. The Competition

Type	Zentalis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.30	2.79	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	188.95% Upside	16,383.89% Upside	10.47% Upside
News Sentiment Rating	Neutral News See Recent ZNTL News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+424.93%
8/12/2024	Wedbush 3 of 5 stars	R. Driscoll Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$4.00	+33.33%
8/12/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00	+566.66%
6/20/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$28.00 ➝ $5.00	+20.77%
6/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$42.00 ➝ $6.00	+38.25%
6/18/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Equal Weight	$38.00 ➝ $8.00	+65.97%
Get the Latest News and Ratings for ZNTL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
6/18/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$32.00 ➝ $10.00	+107.47%
6/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$29.00 ➝ $9.00	+40.62%
11/7/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
11/7/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$15.00	+20.19%
11/11/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$55.00 ➝ $28.00	+35.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:26 AM ET.

ZNTL Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Zentalis Pharmaceuticals is $10.78, with a high forecast of $20.00 and a low forecast of $4.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZNTL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZNTL, but not buy additional shares or sell existing shares.
: According to analysts, Zentalis Pharmaceuticals's stock has a predicted upside of 188.95% based on their 12-month stock forecasts.
: Over the previous 90 days, Zentalis Pharmaceuticals's stock had 1 upgrade by analysts.
: Zentalis Pharmaceuticals has been rated by research analysts at HC Wainwright, Oppenheimer, and Wedbush in the past 90 days.
: Analysts like Zentalis Pharmaceuticals less than other "medical" companies. The consensus rating for Zentalis Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZNTL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Could TSLA reach $500 a share? Free ebook says it’s possible. (Ad)

Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.

To claim your copy, follow this link

This page (NASDAQ:ZNTL) was last updated on 11/5/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target